Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Current Leases (2019 - 2023)

Rein Therapeutics filings provide 5 years of Current Leases readings, the most recent being $48000.0 for Q4 2023.

  • For the quarter ending Q4 2023, Current Leases rose 45.45% year-over-year to $48000.0, compared with a TTM value of $48000.0 through Dec 2023, up 45.45%, and an annual FY2023 reading of $48000.0, up 45.45% over the prior year.
  • Current Leases hit $48000.0 in Q4 2023 for Rein Therapeutics, up from $33000.0 in the prior quarter.
  • The five-year high for Current Leases was $512000.0 in Q3 2020, with the low at $33000.0 in Q4 2022.
  • Median Current Leases over the past 5 years was $115500.0 (2022), compared with a mean of $242875.0.
  • The sharpest move saw Current Leases crashed 81.84% in 2021, then surged 45.45% in 2023.
  • Year by year, Current Leases stood at $446000.0 in 2019, then rose by 14.8% to $512000.0 in 2020, then tumbled by 81.84% to $93000.0 in 2021, then plummeted by 64.52% to $33000.0 in 2022, then skyrocketed by 45.45% to $48000.0 in 2023.
  • According to Business Quant data, Current Leases over the past three periods came in at $48000.0, $33000.0, and $67000.0 for Q4 2023, Q4 2022, and Q3 2022 respectively.